Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2015

View Archived Issues

Integrin alpha-8 identified as a potential target/marker of MM relapse

Sylentis describes ORAI1-targeting siRNAs

CD28-directed therapy extends survival in macaque transplant model

Diaxonhit grants Felicitex license to lead series of small-molecule anticancer compounds

ORIG3N and LabCorp establish LifeCapsule strategic collaboration

MabSpace Biosciences and Jiangsu Hengrui Medicine collaborate on antibody development

Xeltis completes trial of bioabsorbable matrix in patients with one cardiac ventricle

Academics receive grants from U.K. antimicrobial resistance initiative

Ipsen to acquire OctreoPharm Sciences

Studies support rapastinel development for neuropathic pain

DA-6886: safety, tolerability and pharmacokinetics

Ampio Pharmaceuticals reports results from trial of Optina in DME

Afinitor extends progression-free survival in phase III trial in neuroendocrine tumors

Newly discovered inhibitor of HPV DNA amplification described

Isarna Therapeutics' ISTH-0036 receives E.U. orphan drug designation

Biodel starts phase IIb trial comparing rapid-acting insulin BIOD-531 to Humalog

Ono Pharmaceutical patents AXL kinase inhibitors

Bayer presents chymase inhibitors

Ube Industries discloses DNA topoisomerase inhibitors

Daiichi Sankyo develops phosphate transporter inhibitors

Lakewood-Amedex's bisphosphocins show activity against MDR-TB

Silencing SEMA3C and sunitinib show synergy in RCC

Otonomy reveals topline data from phase IIb trial of OTO-104 in Meniere's disease

ReNeuron's retinitis pigmentosa cell therapy receives FDA fast track designation

Visterra and A*STAR collaborate to develop VIS-513 for dengue virus infection

Lpath's iSONEP fails to meet endpoints in phase II wet AMD study

CytRx discloses updated interim results from phase II trial of aldoxorubicin in glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...